Cargando…

Short‐Term Outcomes of a High‐Volume, Low‐Concentration Bolus Starting Dose Technique With Ziconotide: A Case Series

BACKGROUND AND OBJECTIVES: There have been numerous recommendations for a starting dose of intrathecal ziconotide. The therapy remains underutilized partially due to reports of inefficacy and/or intolerance. This study describes short‐term outcomes of a high‐volume, low‐concentration bolus (HVLC‐B)...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lindley, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	INTRATHECAL DRUG DELIVERY
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596839/ https://www.ncbi.nlm.nih.gov/pubmed/34252245 http://dx.doi.org/10.1111/ner.13475

Ejemplares similares

Isotopic Scintigraphy in Intrathecal Drug Delivery Failure: A Single‐Institution Case Series
por: Delhaas, Elmar M., et al.
Publicado: (2020)

Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain
por: McDowell, Gladstone C., et al.
Publicado: (2016)

The Application of Failure Modes and Effects Analysis Methodology to Intrathecal Drug Delivery for Pain Management
por: Saulino, Michael F., et al.
Publicado: (2016)

Targeted Drug Delivery for Chronic Nonmalignant Pain: Longitudinal Data From the Product Surveillance Registry
por: Schultz, David M., et al.
Publicado: (2021)

Low‐Dose Computed Tomography With Two‐ and Three‐Dimensional Postprocessing as an Alternative to Plain Radiography for Intrathecal Catheter Visualization: A Phantom Pilot Study
por: Delhaas, Elmar M., et al.
Publicado: (2019)

Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management
por: Stearns, Lisa J., et al.
Publicado: (2016)

Efficiency and Safety of Aftercare With Intrathecal Baclofen on Location
por: Goslinga‐van der Gaag, Simone M.E., et al.
Publicado: (2019)

Intrathecal Drug Delivery Systems (IDDS): The Implantable Systems Performance Registry (ISPR)
por: Konrad, Peter E., et al.
Publicado: (2016)

DDEL-02. DECREASED TOXICITY OF CONVENTIONAL DOSE CHEMOTHERAPY UTILIZING BODY WEIGHT INSTEAD OF BODY SURFACE AREA FOR DOSING IN YOUNG CHILDREN <6 YEARS OLD ENROLLED ON THE “HEAD START” 4 CLINICAL TRIAL
por: Dhall, Girish, et al.
Publicado: (2020)

ROS Modulating Inorganic Nanoparticles: A Novel Cancer Therapeutic Tool
por: Newton Amaldoss, Maria John, et al.
Publicado: (2022)

Recent Patents on Nasal Vaccines Containing Nanoadjuvants
por: Candela, Francesco, et al.
Publicado: (2022)

Optimizing and Evaluating the Transdermal Permeation of Hydrocortisone Transfersomes Formulation Based on Digital Analysis of the In Vitro Drug Release and Ex Vivo Studies
por: Abdelwahd, Asmae, et al.
Publicado: (2022)

DDEL-06. Drug Delivery to the Pons Using Short-Pulse Focused Ultrasound and Microbubble Exposure for the Treatment of Diffuse Midline Glioma
por: Chattenton, Dani, et al.
Publicado: (2022)

DDEL-09. HIGH DOSE MTX110 (SOLUBLE PANOBINOSTAT) SAFELY ADMINISTERED INTO THE FOURTH VENTRICLE IN A NON-HUMAN PRIMATE MODEL
por: Sirianni, Rachael W, et al.
Publicado: (2020)

DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS
por: Stepien, Natalia, et al.
Publicado: (2020)

Standardised evaluation of medicine acceptability in paediatric population: reliability of a model
por: Vallet, Thibault, et al.
Publicado: (2017)

Evaluation of comparative soft tissue response to bone void fillers with antibiotics in a rabbit intramuscular model
por: Oliver, Rema A, et al.
Publicado: (2019)

Baicalein inhibits non‐small‐cell lung cancer invasion and metastasis by reducing ezrin tension in inflammation microenvironment
por: Zhang, Xiaolong, et al.
Publicado: (2020)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Effect of murine double‐minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys
por: Kawata, Yoshiko, et al.
Publicado: (2020)

Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cells
por: Ohgino, Keiko, et al.
Publicado: (2020)

Exogenous Surfactant as a Pulmonary Delivery Vehicle for Budesonide In Vivo
por: Baer, Brandon, et al.
Publicado: (2020)

Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine
por: Komoto, Kana, et al.
Publicado: (2020)

dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA‐repair‐defective human cancer cells
por: Yokogawa, Tatsushi, et al.
Publicado: (2020)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

DDEL-12. NANOPARTICLE DELIVERY OF DOXORUBICIN FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Ung, Caitlin, et al.
Publicado: (2020)

DDEL-15. NANOTHERAPEUTIC TARGETING OF TUMOR ENDOTHELIUM FOR ENHANCING DRUG DELIVERY PAST THE BLOOD-BRAIN BARRIER
por: Kiguchi, Hiro, et al.
Publicado: (2020)

DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Sasaki, Takahiro, et al.
Publicado: (2020)

DDEL-13. FOCUSED ULTRASOUND MEDIATED BLOOD BRAIN BARRIER DISRUPTION IN A MURINE MODEL OF PONTINE GLIOMA: A SAFETY AND FEASIBILITY STUDY
por: Englander, Zachary, et al.
Publicado: (2020)

DDEL-06. DRUG INTERACTION BETWEEN EVEROLIMUS AND CANNABIDIOL IN PEDIATRIC PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: A SINGLE INSTITUTION EXPERIENCE
por: Sabus, Ashley, et al.
Publicado: (2020)

DDEL-01. ENHANCING DRUG DELIVERY WITH MRgFUS FOR DIFFUSE INTRINSIC PONTINE GLIOMA MODEL
por: Ishida, Joji, et al.
Publicado: (2020)

DDEL-08. CONVECTION-ENHANCED DELIVERY OF NIMUSTINE HYDROCHLORIDE (ACNU) AGAINST PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMAS
por: Saito, Ryuta, et al.
Publicado: (2020)

DDEL-16. UNDERSTANDING OPTIMAL CONVECTION-ENHANCED DELIVERY PHYSICO-CHEMICAL INFUSION PARAMETERS: THE ROLE OF BBB EFFLUX PUMPS IN DRUG DISTRIBUTION AND CLEARANCE
por: Power, Erica, et al.
Publicado: (2020)

DDEL-17. TRIPLE INTRAVENTRICULAR CHEMOTHERAPY FOR TREATMENT OF RELAPSED CHOROID PLEXUS CARCINOMA
por: Lau, Grace, et al.
Publicado: (2020)

DDEL-04. ENGINEERED NANOCARRIERS TO ENHANCE DRUG DELIVERY ACROSS THE BLOOD-BRAIN BARRIER
por: Straehla, Joelle P, et al.
Publicado: (2020)

DDEL-14. SAFETY OF INTERVENTRICULAR METHOTREXATE ADMINISTRATION FOLLOWING RADIATION IN PEDIATRIC PATIENTS WITH MALIGNANT BRAIN TUMORS
por: Rosales, Kristofer, et al.
Publicado: (2020)

DDEL-05. BLOOD-BRAIN BARRIER DISRUPTION AND ENHANCED RADIOSENSITIZERS EXTRAVASATION UPON FOCUSED ULTRASOUND FOR TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Hart, Elvin ‘t, et al.
Publicado: (2020)

DDEL-07. A PHASE I STUDY EXAMINING THE FEASIBILITY OF INTERMITTENT CONVECTION-ENHANCED DELIVERY (CED) OF MTX110 FOR THE TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED DIFFUSE MIDLINE GLIOMAS
por: Zacharoulis, Stergios, et al.
Publicado: (2020)

DDEL-05. Intraventricular therapy with topotecan is feasible and safe: Experience in 50 pediatric patients with various malignant brain tumors
por: Peyrl, Andreas, et al.
Publicado: (2022)

DDEL-07. A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas (DMGs)
por: Zacharoulis, Stergios, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s1u6321m0ipi6aq0orqmubs38a